Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream

Inclusion Criteria: * Adult patients with a clinically confirmed diagnosis of eCRS by a ENT undergoing maximal medical therapy as part of their standard of care. * Having undergone functional endoscopic sinus surgery at least 6 months prior to enrolment. * Participants with an endoscopic bilateral nasal polyp score of ≤5 out of a maximum score of 8 * Score \> 2 on disease severity visual analogue scale (VAS) * A minimum body weight \>=40 kilograms (kg) at screening visit * Gender: Male or female (females of childbearing potential must use adequate birth control methods and not plan to get pregnant during the course of the study). * Informed consent: Willingness to give written informed consent and willingness to participate to and comply with the study. * Age ≥18 but \<80 years. Exclusion Criteria: * Subjects with known hypersensitivity or contraindications to Betamethasone Dipropionate, corticosteroids or topical anaesthesia. * Subjects with sino-nasal abnormalities, disease or implanted devices that prevent application of the therapy. * Previous enrolment in this study. * Subjects currently required systemic corticosteroid use or receiving biologic therapy as part of their disease management plan or who meet the PBS criteria for severe lower airway disease. * Subjects with history or current glaucoma or cataract or if they have abnormal IOP at screening or pre-treatment (abnormal IOP is defined as greater than 21 mm Hg). * Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis. * Subjects with acute sinusitis. * Subjects with known immunodeficiency. * Subjects with Diabetes (Type 1). * Subjects with cystic fibrosis. * Pregnant subjects or subjects currently lactating as the effect on human pregnancy is unknown.